CO - Global Cord Blood Corporation

NYSE - NYSE Delayed Price. Currency in USD
3.0000
-0.5600 (-15.73%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close3.5600
Open3.4400
Bid2.9600 x 800
Ask2.9900 x 1800
Day's Range2.9000 - 3.5200
52 Week Range2.8800 - 7.6900
Volume586,767
Avg. Volume107,879
Market Cap364.653M
Beta (5Y Monthly)0.31
PE Ratio (TTM)10.24
EPS (TTM)0.2930
Earnings DateMar 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 30, 2018
1y Target Est15.00
  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 12-Mar-20 12:00pm GMT

    Q3 2020 Global Cord Blood Corp Earnings Call

  • 3 Medical Companies With the Strength to Weather Coronavirus Fears
    GuruFocus.com

    3 Medical Companies With the Strength to Weather Coronavirus Fears

    Stocks to consider as stimulus bill fails and CVS accelerates labor demand Continue reading...

  • PR Newswire

    Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2020

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal year 2020 ended December 31, 2019.

  • Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2020 Financial Results
    PR Newswire

    Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2020 Financial Results

    Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financial results for the third quarter and first nine months of fiscal year 2020 on Wednesday, March 11, 2020, after the market close.

  • Coronavirus update: 1,383 deaths, more than 63,000 sickened, Expedia predicts impact beyond Q1
    MarketWatch

    Coronavirus update: 1,383 deaths, more than 63,000 sickened, Expedia predicts impact beyond Q1

    There are more than 63,000 cases of COVID-19, the novel coronavirus that was first identified in December in Wuhan, China, and 1,383 deaths, according to the World Health Organization.

  • MarketWatch

    Global Cord Blood's stock rises as it predicts coronavirus impact

    Shares of Global Cord Blood Corp. were up 0.2% in premarket trading on Friday after the Hong Kong-based company said it expects a negative impact to its fourth-quarter performance due to COVID-19, the new coronavirus that has sickened at least 48,000 people, primarily in China. Global Cord Blood, which is an umbilical cord blood banking operator, attribution the projected impact to a combination of factors: some of its workers are not able to return to work due to travel restrictions; hospitals are restricting access to sales representatives, including those employed by Global Cord Blood; and the company's operating costs may rise because it has had to purchase additional medical supplies and equipment for its employees and clients. Global Cord Blood said in a news release that it may adjust its sales target for fiscal 2010 and its "strategy" for fiscal 2021. The company's stock is down 27% over the past year, while the S&P 500 has gained 22%.

  • PR Newswire

    Global Cord Blood Corporation Provides Update on Impact of Coronavirus

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today provided an update on the impact of the 2019 novel coronavirus ("2019-nCoV") on its operations.

  • Global Cord Blood Corporation Appoints Mr. Siu Chuen Cheng as Independent Non-executive Director
    PR Newswire

    Global Cord Blood Corporation Appoints Mr. Siu Chuen Cheng as Independent Non-executive Director

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced the appointment of Mr. Siu Chuen Cheng as a new independent non-executive director to the Board of Directors of the Company (the "Board").

  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 27-Nov-19 1:00pm GMT

    Q2 2020 Global Cord Blood Corp Earnings Call

  • Hedge Funds Have Never Been More Bullish On Global Cord Blood Corporation (CO)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Global Cord Blood Corporation (CO)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]

  • PR Newswire

    PRC NHC Issues New Policy on Cord Blood Banks, Implementation Rules To Be Provided

    Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported that China's National Health Commission ("NHC") recently issued a new policy allowing the relevant Provincial Health Commissions ("PHCs") to approve cord blood bank licenses in 18 pilot Free Trade Zones ("FTZs") in China.

  • PR Newswire

    Global Cord Blood Corporation Announces Results of 2019 Annual General Meeting

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2019 Annual General Meeting, which was held on December 5, 2019, in Hong Kong S.A.R., China.

  • PR Newswire

    Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2020 Financial Results

    Earnings Call Scheduled for 8:00 a.m. ET on November 27, 2019 HONG KONG , Nov. 21, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord ...

  • PR Newswire

    Global Cord Blood Corp Comments on New Regulation

    HONG KONG, Nov. 20, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today commented on a new regulation related to companies in possession of human DNA information relating to the PRC. The Company is still in the process of evaluating the implications of the new regulation on the cord blood banking industry and its business. The Regulation of the People's Republic of China on the Administration of Human Genetic Resources (the "Regulation") has come into effect and the Company recently received an inquiry concerning its impact on the Company.

  • PR Newswire

    Global Cord Blood Corporation Appoints Mr. Jack Chow As an Independent Non-executive Director

    HONG KONG, Nov. 11, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced the appointment of a new independent non-executive director to the Board of Directors of the Company (the "Board"). In order to further strengthen GCBC's Board composition and the Company's leadership position in China's evolving cord blood banking industry, the Board is delighted to announce that Mr. Jack Chow will join the Board as a class B independent non-executive director, effective immediately.

  • Were Hedge Funds Right About Warming Up To Global Cord Blood Corp (CO)?
    Insider Monkey

    Were Hedge Funds Right About Warming Up To Global Cord Blood Corp (CO)?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]

  • PR Newswire

    The Committee for China Cord Fairness Announces Support From The Two Leading Proxy Advisory Firms for Proposals Seeking Minority Shareholder Protections and Governance Enhancements at Global Cord Blood Corporation

    Both ISS and Glass Lewis Support Conditioning All Business Transactions on Approval by a Majority of the Unaffiliated Shareholders ISS Notes "A number of governance shortcomings have been identified" ...

  • PR Newswire

    Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 5, 2019

    HONG KONG, Sept. 20, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2019 annual general meeting of shareholders at its Hong Kong office located at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 5, 2019 (8:00 a.m. U.S. Eastern Standard Time on December 5, 2019).

  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 28-Aug-19 12:00pm GMT

    Q1 2020 Global Cord Blood Corp Earnings Call

  • ACCESSWIRE

    Global Cord Blood Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 28, 2019 / Global Cord Blood Corp. (NYSE: CO ) will be discussing their earnings results in their 2020 First Quarter Earnings to be held on August 28, 2019 at 8:00 AM ...

  • PR Newswire

    Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2020

    1Q20 Added 20,815 New Subscribers Revenues Up 16.9% YoY to RMB273.4 Million ( $39.8 Million )                                   Gross Profit Up 19.4% YoY to RMB227.6 million ( $33.2 million ) Operating ...

  • PR Newswire

    Global Cord Blood Corporation to Report First Quarter Fiscal 2020 Financial Results

    The Company will host a conference call at 8:00 a.m. ET on Wednesday, August 28, 2019 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for 7 days at the same URL as above.

  • PR Newswire

    Global Cord Blood Corporation (NYSE: CO) Urged To Explain Management Compensation in Third Letter From Shareholder Group

    NEW YORK, Aug. 7, 2019 /PRNewswire/ -- The Seiden Group, a law firm headquartered in New York, representing a shareholder group of Global Cord Blood Corporation (NYSE: CO) (the "Company" or "Global Cord") issued a third letter yesterday to Global Cord, which was addressed to the Compensation Committee of the Board of Directors. In the letter, the shareholder group also urged the Compensation Committee to fulfill its obligation to the Company and its shareholders, as described in its most recent 20-F filed with the SEC, to replace the underperforming executives who have not created shareholder value over the past ten years and hire a new team to lead the Company.

  • PR Newswire

    Global Cord Blood Corporation Files Its Annual Report on Form 20-F

    HONG KONG , July 24, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, ...

  • PR Newswire

    Global Cord Blood Corporation (NYSE: CO) Urged in Second Letter From Shareholder Group to Protect Minority Shareholders

    NEW YORK, July 17, 2019 /PRNewswire/ -- The Seiden Group, a law firm headquartered in New York, representing a shareholder group of Global Cord Blood Corporation (NYSE: CO) (the "Company" or "Global Cord") has issued a strong second letter today to the Independent Directors of Global Cord due to the lack of response to the first letter sent on June 17, 2019 and rapidly developing events.  In the current letter, the Company is urged to take certain actions to uphold their fiduciary duty to protect minority shareholder rights. Abide by basic corporate governance and transparency and announce the names of financial advisors and preserve all instructions in email, including the firms contacted during the "market check" process by the financial advisor.